Search

Gary G. Koch

Comments on 'Sample size formula for a win ratio endpoint' by RX Yu and J. Ganju
Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial
Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection
Power and sample size calculation for the win odds test: application to an ordinal endpoint in COVID-19 trials
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19)
Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID‐19: Design and rationale for the DARE‐19 study
Adjusted win ratio with stratification: Calculation methods and interpretation

Published with Wowchemy — the free, open source website builder that empowers creators.